-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

905.P1.81 905. Outcomes Research—Lymphoid Malignancies: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Joshua Richter, MD1, Peggy Lin, PhD2*, Viviana Garcia-Horton, PhD3*, Patricia Guyot, PhD4*, Erin Singh, PhD2*, Zheng-Yi Zhou, PhD5* and Mark Sievert, PhD2*

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Sanofi, Cambridge, MA
3Analysis Group, Inc., New York, NY
4Sanofi, Chilly-Mazarin, France
5Analysis Group Inc., London, MA, United Kingdom

Faouzi Djebbari1*, Grant Vallance1*, Nanda Basker2*, Fotios Panitsas3*, Alexandros Rampotas4,5*, Gina Sangha6*, Beena Salhan7,8,9*, Farheen Karim, MD10*, Firas Al-kaisi, MD11*, Amy Gudger12*, Loretta Ngu13*, Matt Poynton14*, Ho Pui Jeff Lam15*, Lowri Morgan16*, Laura Yang17*, Jennifer Young18*, Mairi Walker19*, Ismini Tsagkaraki20*, Laura Anderson, PhD21*, Saleena Rani Chauhan22*, Rebecca Maddams23*, Lesley Stirton24*, Margarita Triantafillou25*, Steve Prideaux26*, Abubaker Obeidalla27*, Ceri Bygrave16*, Supratik Basu28,29* and Karthik Ramasamy1

1Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
2University Hospital Southampton, Southampton, United Kingdom
3Laiko General Hospital, Athens, Greece
4Oxford University Clinical Academic Graduate School, Oxford, United Kingdom
5Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom
6Milton Keynes Hospital, Milton Keynes, United Kingdom
7Good Hope Hospital, Birmingham, United Kingdom
8Solihull Hospital, Solihull, United Kingdom
9Birmingham Heartlands Hospital, Birmingham, ENG, United Kingdom
10Royal Wolverhampton NHS Trust, WMRC, Wolverhampton, United Kingdom
11Royal Derby Hospital, Derby, ENG, United Kingdom
12Queen Elizabeth Hospital, Birmingham, United Kingdom
13Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom
14Royal Berkshire Hospital, Reading, United Kingdom
15Guy's and St Thomas NHS Foundation Trust, London, ENG, United Kingdom
16University Hospital of Wales, Cardiff, United Kingdom
17University Hospitals Sussex NHS Foundation Trust, Worthing, United Kingdom
18Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
19University Hospital Crosshouse, Crosshouse, United Kingdom
20Stoke Mandeville Hospital, Aylesbury, United Kingdom
21Royal United Hospital, Bath, United Kingdom
22Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom
23Poole Hospital, Poole, United Kingdom
24Beatson Oncology Centre, Glasgow, United Kingdom
25Manchester Royal Infirmary, Manchester, United Kingdom
26Great Western Hospital, Swindon, United Kingdom
27Wexham Park Hospital, Slough, United Kingdom
28The Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, United Kingdom
29The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom

Swetha Challagulla, MS1*, Nehemiah Kebede2*, Sanika Rege, MS, PhD2*, Raisa R. Volodarsky, PharmD, RPh1*, Kojo Osei-Bonsu, MD, MPH, MBA1* and Sudeep Karve3*

1Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
2OPEN Health Evidence and Access, Bethesda, MD
3Abbvie Inc., North Chicago, IL

Shebli Atrash, MD1, Philippe Thompson-Leduc, MSc2*, Ming-Hui Tai, PhD3*, Shuchita Kaila, PhD3*, Kathleen Gray, PhD3*, Isabelle Ghelerter4*, Marie-Hélène Lafeuille, MA4*, Patrick Lefebvre, MA4* and Adriana C Rossi, MD5*

1Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
2Analysis Group, Inc, Montreal, QC, Canada
3Janssen Scientific Affairs, LLC, Horsham, PA
4Analysis Group, Inc., Montreal, QC, Canada
5Division of Hematology and Oncology, Weill Cornell Medicine (at the time the study was conducted), New York, NY

Darcy R. Flora1*, Susan K. Parsons, MD, MRP2, Nicholas Liu, PharmD3*, Kristina S. Yu, PhD, MPH, RPh3*, Katie Holmes4*, Carlos Flores, MPH5*, Michelle A. Fanale, MD3, Supriya Kumar4*, Andy Surinach, MPH5*, Rachel Byrd1* and Andrew M. Evens, DO, MMSc6

1GRYT Health, Rochester, NY
2Division of Hematology/Oncology, Tufts Medical Center, Boston, MA
3Seagen Inc., Bothell, WA
4Ipsos Healthcare, New York, NY
5Genesis Research, Hoboken, NJ
6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Eberechukwu Onukwugha, PhD1*, Tsung-Ying Lee, BSPharm, MClinPharm1*, Johnson Abree, MS, MBA1*, Catherine Cooke, PharmD, BCPS, PAHM2*, Summers Amanda, BS1*, Keri Yang, PhD, MBA, MPH, MS3*, Sizhu Liu, MS3*, Boxiong Tang, MD, PhD3 and Yared Jean, MD4*

1Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD
2Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD
3BeiGene, Ltd., Emeryville, CA
4Department of Medicine, University of Maryland School of Medicine, Baltimore, MD

Inna Gong, MD, PhD1, Matthew C. Cheung, MD, MSc2,3, Kelvin Chan, MD, PhD3,4,5*, Sumedha Arya, MD1, Neil Faught, MSc5*, Ning Liu, MSc, PhD2*, Oreofe O. Odejide, MD, MPH6, Gregory A. Abel, MD, MPH7, Michael Raphael, MD3*, Anca Prica, MD8, Christopher Booth9*, Thomas M. Kuczmarski, MD10* and Lee Mozessohn, MD5,11

1Department of Medicine, University of Toronto, Toronto, ON, Canada
2ICES, Toronto, ON, Canada
3Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4Cancer Care Ontario, Toronto, Canada
5Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
6Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
7Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA
8Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
9Queen’s University Cancer Research Institute, Division of Cancer Care and Epidemiology, Kingston, ON, Canada
10Department of Medicine, Brigham and Women's Hospital, Boston, MA
11Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

Tamara P. Miller, MD1,2, Nicholas P. DeGroote, MPH3*, Lauren Pommert, MD4, Oluwafunbi Awoniyi1*, Sarah Board5*, Ngozi Ugboh1*, Vivek Joshi1*, Nicholas Ambrosino, PharmD5*, Allison Weisnicht, MD6*, Heidi Hsiao7*, Melanie Brooke Bernhardt, MS, PharmD8*, Eric S Schafer, MD9*, Maureen M. O'Brien, MD10, Sharon M. Castellino, MD, MSc11 and Laura B. Ramsey, PhD12*

1Emory University, Atlanta, GA
2Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Decatur, GA
3Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
4Cincinnati Children's Medical Center, Cincinnati, OH
5Cincinnati Children's Hospital Medical Center, Cincinnati
6Department of Pediatrics, Baylor College of Medicine, Houston, TX
7Texas Children's Hospital, Houston, TX
8Baylor College of Medicine, Houston
9Baylor College of Medicine, Texas Children's Hospital, Houston, TX
10Cincinnati Children's Hospital Medical Center, Cincinnati, OH
11Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
12Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Victoria A. Vardell, MD1, Daniel A. Ermann, MD2, Srinivas K. Tantravahi, MBBS3, Brian McClune, DO4*, Mary Nicole Steinbach, NP5*, Ghulam Rehman Mohyuddin, MD6, Amandeep Godara, MD6 and Douglas W. Sborov, MD, MSc6

1Department of Internal Medicine, University of Utah, Salt Lake City, UT
2Department of Hematology/Oncology, Huntsman Cancer Institute, University of Utah, Omaha, NE
3Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
4Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City
5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institue, Salt Lake City, UT
6Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, Salt Lake City, UT

Farrukh T. Awan, MD1, Andrew J. Belli2*, Eric Hansen, MS3*, Mimi Chung3* and Ching-Kun Wang, MD3*

1Division of Hematologic Malignancies and Stem Cell Transplantation, Department of Internal Medicine, UT Southwestern, Dallas, TX
2COTA, Inc., New York, NY
3COTA, Inc., Boston, MA

Natalia Neparidze, MD1, Krystal W. Lau2*, Xiaoliang Wang, PhD, MPH3*, Amy J. Davidoff, PhD4*, Scott F. Huntington, MD, MPH5, Omer Hassan Jamy, MD6, Gregory Calip, PhD7*, Harsh Shah, DO8, Deborah M. Stephens9, Rebecca A. Miksad, MD, MPH3*, Ravi Parikh, MD10*, Samuel Takvorian11*, Gaurav Goyal, MD12 and Erlene K Seymour, MD3

1Section of Hematology, Yale University, New Haven, CT
2Flatiron Health Inc., Flatiron Health Inc., New York, NY
3Flatiron Health Inc., New York, NY
4National Cancer Institute, NIH, Bethesda, MD
5Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
6Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
7Flatiron Health Inc, New York, NY
8Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT
9Huntsman Cancer Institute, Huntsman Cancer Institute, Salt Lake City, UT
10Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA
11Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
12Research Collaborator (limited-tenure), University of Alabama at Birmingham, Birmingham, AL

Carolina Velez-Mejia, MD1*, Qianqian Liu, PhD2,3*, Joel E Michalek, PhD3* and Adolfo Enrique Diaz Duque, MD4

1Internal Medicine Residency Program, University of Texas Health at San Antonio, San Antonio, TX
2Hematology-Oncology Division, University of Texas Health at San Antonio, San Antonio, TX
3Department of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, TX
4University of Texas Health at San Antonio, San Antonio, TX

David Hughes, PharmD1*, Lynnette Henshaw, PharmD2*, Frances Blevins, PA-C3*, Camille V Edwards, MD4, Adam Lerner, MD5, John Mark Sloan, MD6 and Vaishali Sanchorawala, MD7

1Department of Pharmacy, Boston University School of Medicine and Boston Medical Center, Boston, MA
2Pharmacy, Boston Medical Center, Boston, MA
3Department of Hematology/Oncology, Boston University, Boston, MA
4Amyloidosis Center, Boston University, Boston, MA
5Department of Hematology and Oncology, Boston Medical Center, Boston, MA
6Boston University S Medical Center, Boston, MA
7Amyloidosis Center, Boston Medical Center Corporation, Boston, MA

Jacqueline Barrientos, MD, MS1, Anthony R. Mato, MD2, Nilanjan Ghosh, MD, PhD3, Jeff P. Sharman, MD4, Meghan Gutierrez, BA5*, Maoko Naganuma, MSc6*, Sandhya Upasani, MS6*, Divi Alagappan, PhD7*, Qing Huang, PhD7*, Alex Young, PharmD6* and Danielle M. Brander, MD8

1Division of Medical Oncology and Hematology, Northwell Health Cancer Institute Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
2Memorial Sloan Kettering Cancer Center, New York, NY
3Levine Cancer Institute, Charlotte, NC
4Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR
5Lymphoma Research Foundation, New York, NY
6Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
7Janssen Scientific Affairs, LLC, Horsham, PA
8Duke University Health System, Durham, NC

Aisha S Patel, MBBS, MRCP1*, Jahanzaib Khwaja2*, Helen McCarthy, MBBS FRCP PhD FRCPath3,4*, Guy Pratt, MD FRCP FRCPath5*, Jaimal Kothari, Bm BCh6*, Jindriska Lindsay, FRCPath7*, Roger G Owen, MD8*, Josephine Crowe9*, Dima El-Sharkawi10*, Nilima Parry-Jones, MBBS, FRCP, MD, FRCPath11, Kirsty Cuthill, MA MBBS FRCP FRCPath PhD12*, Maria Atta, MD13*, Kim Linton14*, Agapi Parcharidou, MD15*, Charalampia Kyriakou, MD, PhD16,17, Deborah Turner, MBBS, BsC, MRCP, FRCPath18*, Jeffery Smith, MBChB, MRCP, FRCPath19*, Simona Gatto20*, Nicola Crosbie21*, Suzanne O Arulogun, MBBS, FRACP, FRCPA22 and Shirley D'Sa, MD, FRCPath2,23*

1Department of Haematology, University College London Hospitals NHS Foundation Trust, London, ENG, United Kingdom
2Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
3Royal Bournemouth Hospital, Bournemouth, United Kingdom
4University Hospitals Dorset, Bournemouth, United Kingdom
5University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
6Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
7East Kent Hospitals University NHS Foundation Trust, Canterbury, ENG, United Kingdom
8St. James's University Hospital, Leeds, United Kingdom
9Royal United Hospital, Bath, United Kingdom
10The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
11Aneurin Bevan University Health Board, Abergavenny, United Kingdom
12King's College Hospital NHS Foundation Trust, London, United Kingdom
13Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom
14The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom
15Northwick Park Hospital, London, United Kingdom
16University College London Hospital, UCLH Centre for Waldenström and Related Conditions, London, United Kingdom
17London North West University Healthcare NHS Trust and University College London Hospital, London, United Kingdom
18Torbay and South Devon NHS trust, Torbay, United Kingdom
19The Clatterbridge Cancer Centre NHS Foundation Trust/ Liverpool University Hosptials NHS Trust, Liverpool, United Kingdom
20Cardiff and Vale University Hospital, Cardiff, United Kingdom
21University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
22University College London Hospitals NHS Foundation Trust, London, United Kingdom
23University College London Hospitals NHS Foundation Trust, UCLH Centre for Waldenström’s Macroglobulinemia and Related Conditions, London, United Kingdom

Paula Rodríguez-Otero, MD, PhD1*, Ali Mojebi2*, Dieter Ayers2*, Devender Dhanda3*, James Farrell3*, Faith E. Davies, MD4, Michel Delforge5, Katja Weisel6*, Kevin Towle2*, Tom Marshall3*, Clyde Caisip2* and Shannon Cope2*

1Clínica Universidad de Navarra, Pamplona, Spain
2Evidence Synthesis & Decision Modeling, PRECISIONheor, Vancouver, BC, Canada
3Bristol Myers Squibb, Princeton, NJ
4NYU Langone Health, New York, NY
5University Hospital Leuven, Leuven, Belgium
6Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

Ming-Hui Tai, PhD1*, Qian Cai1*, Alex Z. Fu, PhD2,3*, Vipin Khare1* and Shuchita Kaila, PhD1*

1Janssen Scientific Affairs, LLC, Horsham, PA
2Janssen Scientific Affairs, LLC, Titusville, NJ
3Georgetown University Medical Center, Washington, DC

*signifies non-member of ASH